**Background:** Photodynamic therapy using photosensitive materials offers a promising approach for rapid microbial eradication by generating reactive oxygen species (ROS) upon light activation. Carbon dots (CDs) are biocompatible, inexpensive nanomaterials with antimicrobial potential. This study aimed to enhance the photodynamic antimicrobial activity of nitrogen-doped arginine carbon dots (Arg CDs) by conjugating them with fluorescein sodium salt (FSS) or riboflavin (RBF), both of which are non-toxic and used in clinical ophthalmic applications. The goal was to achieve rapid pathogen killing without toxicity, addressing limitations of previous modifications that caused toxic effects.
**Methods:** Arg CDs were synthesized via microwave-assisted carbonization of citric acid and arginine (3:1 weight ratio) at 1000 W for 3 minutes. The CDs were then conjugated with FSS or RBF using N,N'-carbonyldiimidazole (CDI) as a coupling agent. Characterization included HR-TEM, DLS, zeta potential, FT-IR, UV-Vis, and fluorescence spectroscopy. Cytotoxicity was assessed using L929 fibroblast cells with MTT assay at concentrations 50–1000 μg/mL. Hemocompatibility was evaluated via hemolysis and blood clotting assays at 1000 μg/mL. Antimicrobial activity was tested against Gram-negative (E. coli, K. pneumoniae), Gram-positive (S. aureus, B. subtilis), and fungal (C. albicans) pathogens using microtiter dilution to determine MIC. Photodynamic activity against B. subtilis was tested under UV-A light (315–400 nm, 300 W) for 5, 15, and 30 minutes, compared to dark conditions.
**Key Results:** Arg CDs were spherical, 0.5–5 nm in size, with a graphitic lattice spacing of 0.28 nm. Zeta potentials were −5.4 ± 4.8 mV (Arg), −15.8 ± 5.2 mV (Arg-FSS), and −24.5 ± 10.2 mV (Arg-RBF). Quantum yields at 345 nm excitation were 12.5 ± 0.2% (Arg), 11.9 ± 2.7% (Arg-FSS), and 8.1 ± 0.9% (Arg-RBF); at 520 nm excitation, Arg-FSS and Arg-RBF had QY of 9.1 ± 2.0% and 23.2 ± 5.6%, respectively. Cytotoxicity: at 1000 μg/mL, cell viability was 63.0 ± 6.5% (Arg), 77.8 ± 2.2% (Arg-FSS), and 91.2 ± 0.7% (Arg-RBF). Hemolysis ratios were 3.2 ± 0.6%, 2.9 ± 0.4%, and 3.3 ± 0.8% for Arg, Arg-FSS, and Arg-RBF, respectively (all <5%). Blood clotting indices were 85.9 ± 2.5, 84.6 ± 5.0, and 87.5 ± 6.5. MIC values (mg/mL) for Arg CDs: E. coli 3.12, K. pneumoniae 6.25, S. aureus 3.12, B. subtilis 1.50, C. albicans 6.25. Modified CDs showed approximately two-fold higher MIC values. Photodynamic testing: after 30 min UV-A exposure, Arg-RBF CDs reduced B. subtilis viability to 12 ± 6%, while Arg and Arg-FSS CDs showed ~50% viability. Under dark conditions, no significant inhibition was observed. UV-A alone resulted in 93 ± 3.8% bacterial viability.
**Clinical Implications:** Arg-RBF CDs demonstrate rapid, broad-spectrum antimicrobial activity upon UV-A activation with excellent biocompatibility, making them promising for photodynamic therapy applications such as treating corneal ulcers or other localized infections. The non-toxic nature at high concentrations (up to 1000 μg/mL) supports potential intravenous use. Further in vivo studies are needed to confirm safety and efficacy.